Johnson & Johnson said on Friday an interim analysis showed its drug Carvykti met the main goal of improving progression-free survival in patients with a type of blood cancer in a late-stage study. The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies. Carvykti, developed by J&J and its China-focused partner Legend Biotech Corp, was approved by the U.S. health regulator last year based on an early-to mid-stage study to treat relapsed or refractory multiple myeloma patients who had received four or more prior lines of therapy.
The world's biggest healthcare products' maker continued with its long streak of earnings beat and missed revenue estimates.
Berkshire Hathaway CEO Warren Buffett is widely considered one of the best stock pickers of all time, and for good reason. Here are three top Buffett stocks that could make you richer in 2023 and beyond. Ally Financial (NYSE: ALLY) is an automotive-oriented online bank.